Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR MUTATION
EGFR MUTATION
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitted) and included 160 patients with lung adenocarcinoma subtype. The patients had EGFR mutations (exon 19 deletions or L858R), and improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/3791
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/1854
Rating
4
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Erlotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
22285168
Drugs
Drug NameSensitivitySupported
ErlotinibSensitivitytrue